

vLAB® ADC INTELLIGENCE

SEARCH SPACE

5206 genes
available for KD/KO

1348 biosamples
mapped to patient subtypes

113 drugs & their combinations
incl. 6 ADCs & 21 payloads



Partner's samples



Partner's molecules

PRESET WORKFLOWS

ADC discovery & positioning

- In which indications is my payload / ADC most effective?
- How selective is my ADC?
- What are the predictive biomarkers of sensitivity / resistance?

ADC payload synergy & combinations

- Which payload pairs are the most synergistic?
- Which ADC - small molecule pairs are the most synergistic?
- Which genes should I target alongside my drug to improve efficacy?

ADC clinical translation

- How translatable are my in vitro ADC efficacy results?
- What clinically-relevant biomarkers can I identify early to inform patient inclusion/exclusion criteria?

TURBINE'S PUBLIC, PROPRIETARY & LICENSED DATASETS



- **1400** cell lines
- **50+** immune cell types
- **1000+** PDX models
- **100,000** patient profiles



- **200+ drugs & combinations**
SoC, payloads, PROTACs & full ADCs
- **Targeted response data**
for PDX and patient library



Turbine's Lab-in-the-Loop continuously turns data into predictions, predictions into targeted experiments, and experimental results into more powerful Virtual Assays.

revvity
REFERENCE LAB

ADC Intelligence



Simulate small molecule and ADC responses in virtual cells to rank compounds for your target indications, discover synergistic combinations, and link therapies to the molecular profiles most likely to respond.

- Drug sensitivity
- Drug-drug combination synergy
- Drug + Gene KO

Target Discovery & De-Risk




The Target Discovery and De-risk model supports target discovery by identifying key molecular drivers of cancer. It highlights high-confidence, disease-relevant targets and enables users to prioritize them based on biological significance, patient prevalence, and therapeutic potential.

- Gene knockout (CRISPR KO)
- Gene knockdown (KD)
- pRNAseq
- Drug modifier screen (KO & KD)


Dashboard

- In silico experiments
- Data packages
- In vitro experiments
- Knowledge hub


Target Discovery 1.0 RC 1 · Completed



CSO across lineage and selected mutation



Drug sensitivity by biological sample



Experiment details

Model
Target Discovery 1.0 RC 1

Started
23 September 2026, 2:11



Runtime
1h 25 min

Experiment units
5,392

LEADING PHARMA ARE USING OUR PLATFORM TO ACCELERATE DISCOVERY



SEE OUR LATEST TUTORIALS AND PUBLICATIONS



INTERESTED IN A LIVE DEMO?



Neeraj Rao

Director, Business Development
neeraj.rao@turbine.ai



Pier Giorgio Pacifici

Director, Business Development
pier.giorgio.pacifici@turbine.ai